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Abstract
The His274?Tyr (H274Y) oseltamivir (Tamiflu) resistance mutation causes a substantial decrease in the total levels of
surface-expressed neuraminidase protein and activity in early isolates of human seasonal H1N1 influenza, and in the swine-
origin pandemic H1N1. In seasonal H1N1, H274Y only became widespread after the occurrence of secondary mutations that
counteracted this decrease. H274Y is currently rare in pandemic H1N1, and it remains unclear whether secondary mutations
exist that might similarly counteract the decreased neuraminidase surface expression associated with this resistance
mutation in pandemic H1N1. Here we investigate the possibility of predicting such secondary mutations. We first test the
ability of several computational approaches to retrospectively identify the secondary mutations that enhanced levels of
surface-expressed neuraminidase protein and activity in seasonal H1N1 shortly before the emergence of oseltamivir
resistance. We then use the most successful computational approach to predict a set of candidate secondary mutations to
the pandemic H1N1 neuraminidase. We experimentally screen these mutations, and find that several of them do indeed
partially counteract the decrease in neuraminidase surface expression caused by H274Y. Two of the secondary mutations
together restore surface-expressed neuraminidase activity to wildtype levels, and also eliminate the very slight decrease in
viral growth in tissue-culture caused by H274Y. Our work therefore demonstrates a combined computational-experimental
approach for identifying mutations that enhance neuraminidase surface expression, and describes several specific
mutations with the potential to be of relevance to the spread of oseltamivir resistance in pandemic H1N1.
Citation: Bloom JD, Nayak JS, Baltimore D (2011) A Computational-Experimental Approach Identifies Mutations That Enhance Surface Expression of an
Oseltamivir-Resistant Influenza Neuraminidase. PLoS ONE 6(7): e22201. doi:10.1371/journal.pone.0022201
Editor: Ron A. M. Fouchier, Erasmus Medical Center, Netherlands
Received May 5, 2011; Accepted June 16, 2011; Published July 20, 2011
Copyright:  2011 Bloom et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: JDB was funded by a Beckman Institute postdoctoral fellowship at the California Institute of Technology. JSN was funded by an Amgen undergraduate
summer research fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: baltimo@caltech.edu
Introduction
In molecular evolution, multiple mutations are often required to
confer an advantageous phenotypic change. Frequently, one
mutation directly causes a beneficial functional alteration (such
as a shift in substrate specificity or drug resistance), but is
deleterious to protein-level properties such as folding, stability, or
expression. A secondary mutation bolsters the protein-level
properties damaged by the functional mutation, but by itself
may confer no major adaptive benefit. Both mutations are needed
to yield a protein that possesses the beneficial functional alteration
and the requisite protein-level properties. Examples of this
phenomenon may include the evolution of antibiotic resistance
[1,2], viral immune escape [3], steroid-receptor specificity [4],
cytochrome P450 enzymatic activity [5,6], HIV co-receptor usage
[7], and influenza antiviral resistance [8].
When the functional mutation occurs first and is followed by a
secondary mutation that repairs protein-level properties, the
secondary mutation is typically referred to as ‘‘compensatory.’’
However, if an initial occurrence of a secondary mutation enables
the protein to tolerate the subsequent functional mutation, the
secondary mutation is referred to as ‘‘permissive’’ [4]. It is often
impossible to determine which of these two scenarios actually
occurred, but in some cases it appears that evolution proceeded via
permissive mutations [4,8]. This fact raises the tantalizing prospect
that it may be possible to predict secondary mutations that could
foreshadow future evolutionary change. In this paper, we explore
the possibility of identifying mutations of possible relevance for the
evolution of resistance to the neuraminidase-inhibitor oseltamivir
(Tamiflu) in the 2009 swine-origin pandemic H1N1 influenza.
Resistance to oseltamivir is conferred on N1 influenza
neuraminidases by the His274?Tyr mutation (H274Y, N2
numbering), which causes a subtle structural change in the
protein’s active site that weakens the binding of oseltamivir [9].
Although H274Y could occasionally be identified in human
seasonal H1N1 isolates from people taking oseltamivir [10], it was
thought that this mutation was unlikely to spread appreciably. The
reason for this view was that H274Y dramatically attenuated a
variety of seasonal H1N1 strains in tissue culture and animal
models, including A/WSN/1933 [11], A/Texas/36/1991 [12],
A/New Caledonia/20/1999 [13], and A/Mississippi/3/2001
[14]. This attenuation coincided with a protein-level defect caused
by H274Y that decreased the amount of neuraminidase expressed
on the cell surface [8]. But by 2007, H274Y no longer detectably
attenuated seasonal H1N1 isolates [14–16], and viruses carrying
that mutation began to spread globally, going to near fixation in
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preceded by secondary mutations that counteracted the decrease
in neuraminidase surface expression caused by H274Y [8].
In the spring of 2009, human seasonal H1N1 was displaced by a
new pandemic swine-origin H1N1 strain that continues to
circulate globally [20,21]. Currently, only about 1% of tested
pandemic H1N1 isolates have carried H274Y [22,23]. Most of
these resistant isolates have been from immunocompromised
patients or individuals taking oseltamivir, with only a few reported
cases of H274Y virus being transmitted in healthy untreated adults
[22,23].
At the protein level, H274Y causes the same defect in
neuraminidase surface expression observed in early seasonal
H1N1. Specifically, H274Y causes a substantial decrease in the
total protein and activity expressed on the surface of cells
transfected with plasmids encoding pandemic H1N1 neuramini-
dase [8], while pandemic H1N1 viruses with H274Y possess
between four and 10-fold less total neuraminidase activity [24–26].
However, as discussed immediately below, it remains unclear
whether this decrease meaningfully attenuates viral fitness.
A number of experimental studies have compared the growth or
transmission of matched isolates of wildtype and H274Y pandemic
H1N1. In MDCK-derived cell lines, H274Y virus grew slightly but
detectably worse than wildtype in five of eight cases [24,27–30]; in
the other three cases, there was no discernible difference
[25,29,30]. H274Y virus grew slightly more poorly than its
wildtype counterpart in differentiated human airway epithelium
cells [25]. Upon direct inoculation of high doses into ferrets or
mice, both wildtype and H274Y viruses replicated efficiently and
caused disease in all studies [27–31]. Similarly, in all studies, both
wildtype and H274Y viruses transmitted by direct contact with
100% efficiency between co-caged ferrets [29,31] or guinea pigs
[29]. Perhaps the most biologically relevant experimental measure
of viral fitness is airborne transmission in ferrets or guinea pigs. In
two of five comparisons, both wildtype and H274Y virus
transmitted rapidly to all exposed animals in the experimental
conditions used [29,30]. But in the three comparisons without
complete rapid transmission, the H274Y virus either transmitted
markedly more slowly [30] or completely failed to infect some of
the exposed animals [27,29]. The authors of these studies differ
about whether their results imply attenuation by H274Y – clearly,
pandemic H1N1 is not severely crippled by the mutation as was
early seasonal H1N1. This difference in the extent of attenuation
caused by reduced neuraminidase levels could be due to as yet
undefined differences elsewhere in the viral genome, such as in
hemagglutinin receptor avidity [32]. However, from an evolution-
ary perspective, a reduction of viral fitness by even a few percent
would likely prevent the spread of H274Y in pandemic H1N1,
since only a small fraction of infected individuals use oseltamivir
[33].
We therefore considered it worthwhile to investigate whether we
could identify secondary mutations that counteract the decreased
neuraminidase surface expression caused by H274Y in pandemic
H1N1. We began by testing the ability of several computational
approaches to retrospectively identify secondary mutations that
increase the total surface-expressed neuraminidase activity in
seasonal H1N1. We find that the PIPS computational approach
[34] is the most capable of correctly identifying secondary
mutations in this retrospective test. We then use this computa-
tional approach to predict 12 candidate secondary mutations to
pandemic H1N1. We experimentally screen these mutants, and
show that several of them do indeed increase the total surface-
expressed protein and activity of H274Y pandemic H1N1
neuraminidase. Combining two of these secondary mutations
with H274Y restores surface-expressed activity to approximately
wildtype levels, and also rescues the modest attenutation that
H274Y causes for viral growth in tissue culture. Our work
therefore identifies several secondary mutations that have the
potential to be of relevance for the evolution of oseltamivir
resistance in pandemic H1N1.
Results
Retrospective testing of computational approaches for
identifying important secondary mutations in seasonal
H1N1
The goal of our study is to predict secondary mutations that
enhance the surface-expressed activity and protein levels for
H274Y pandemic H1N1 neuraminidase. There are various
computational approaches that conceivably could be applied
towards this goal. We therefore began by testing the ability of
several computational approaches to retrospectively identify
important secondary mutations from the evolution of seasonal
H1N1 neuraminidase.
The A/New Caledonia/20/1999 seasonal H1N1 strain is
attenuated by H274Y [13], while the A/Brisbane/59/2007 strain
is not attenuated by this mutation [14] and is an immediate
ancestor of the lineage of oseltamivir-resistant viruses that went to
fixation beginning in 2007. We performed assays to measure both
the total surface-expressed neuraminidase activity and protein
levels in mammalian cells transfected with plasmids encoding
wildtype and H274Y neuraminidase proteins from these two
strains. As described previously [8], H274Y caused an approxi-
mately two-fold decrease in surface-expressed neuraminidase
protein and activity for the 1999 strain (Figure 1). In comparison,
the wildtype 2007 neuraminidase was expressed on the cell surface
at over 1.5-fold higher levels than its 1999 counterpart, and the
relative magnitude of the decrease caused by H274Y was
substantially smaller (Figure 1).
A total of 12 amino acid mutations separate the neuraminidases
from these strains (H45N, V48I, K78E, E214G, R222Q, V234M,
G249K, T287I, K329E, D344N, G354D, and D382N; N1
numbering). Two of these mutations (R222Q and V234M) have
been shown experimentally to be sufficient to alleviate the
attenuation of viral growth in tissue culture caused by H274Y in
the background of the 1999 neuraminidase [8]. A third mutation
(D344N) has been suggested to enhance neuraminidase substrate
affinity [15,35,36]. We progressively added these mutations to the
1999 neuraminidase in the order that they appeared in natural
sequences (V234M, then R222Q, then D344N). When all three
mutations were added to the 1999 neuraminidase, it exhibited
similar levels of total surface-expressed protein and activity to the
2007 neuraminidase, both in the presence and absence of H274Y
(Figure 1). Of the remaining mutations, three (V48I, E214G, and
D382N) have been tested previously [8]. In the background of an
H274Y seasonal H1N1 neuraminidase, none of these mutations
caused a substantial change in surface-expressed neuraminidase
protein or activity. Since the divergence in surface-expressed
protein and activity between 1999 and 2007 is explained by the
three mutations R222Q, V234M, and D344N, for the purpose of
the retrospective testing in this section, we placed these three
mutations in one group. We then placed all of the remaining
mutations in another group – although we stress that some of these
remaining mutations have not been explicitly tested for their effect
on neuraminidase surface-expressed activity.
We next sought to test whether computational approaches could
identify the three known enhancing mutations from the complete
set of mutations that separated the 1999 and 2007 strains. We
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identify these three mutations might also be able to predict new
mutations that enhance the surface expression of pandemic H1N1
neuraminidase. Because several of the candidate computational
approaches utilize structural data, we restricted the analysis to the
mutations that occurred in the crystallized [37] ectodomain of the
neuraminidase (this excludes mutations H45N, V48I, and K78E).
Our test therefore consisted of assessing the ability of the
computational approaches to distinguish R222Q, V234M, and
D344N from the remaining six ectodomain mutations (E214G,
G249K, T287I, K329E, G354D, and D382N) that occurred
during the divergence of the 1999 and 2007 strains.
We tested four different computational approaches. CUPSAT is
a computer program that combines structural information with
statistically derived potentials to predict the changes in protein
stability associated with amino acid mutations [38]. FoldX is a
computer program that uses a full atomic description of a protein’s
structure to predict mutational effects on protein stability [39].
The ‘‘consensus’’ approach assumes that the individual contribu-
tion of a mutation has a direct logarithmic (Boltzmann-like)
relationship to its frequency in a sequence alignment of
homologous proteins, such that the consensus residue is always
assumed to be the most favorable [40–42]. Finally, PIPS is a
method that we developed to infer mutational effects based on an
analysis of protein phylogenies, and which has been shown to be
able to predict secondary mutations that alleviate temperate-
sensitive defects in influenza hemagglutinin [34]. The improved
implementation of the PIPS approach used here is described in
detail in the Materials and Methods section, as are the datasets
used for the CUPSAT, FoldX, and consensus predictions.
Figure 2 shows the ability of each of the four computational
approaches to distinguish R222Q, V234M, and D344N from the
other six mutations. Neither CUPSAT nor FoldX showed any
efficacy. Both of these methods placed the predicted effects of the
nine actual ectodomain mutations near the center of the
distribution for all possible neuraminidase mutations, and failed
to separate R222Q, V234M, and D344N from the other six
mutations. The consensus approach did identify the nine actual
ectodomain mutations as being among the most preferable of all
possible mutations, although this is a somewhat tautological result
since by construction the approach prefers mutations that are
prevalent in natural sequences. However, the consensus approach
Figure 1. The three secondary mutations V234M, R222Q, and D344N largely explain the differences in total surface-expressed
activity and protein between 1999 and 2007 seasonal H1N1 neuraminidases. Shown are wildtype (WT) and indicated mutants of the A/
New Caledonia/20/1999 neuraminidase, in addition to WT and H274Y neuraminidases from the A/Brisbane/59/2007 (BR07) strain. All neuraminidases
contain C-terminal epitope tags, except for the untagged WT and H274Y A/New Caledonia/20/1999 variants. For the measurements, 293T cells were
transfected with plasmids encoding the neuraminidase proteins. After 20 hours, the cells were assayed for the total surface-expressed neuraminidase
activity (top panel) or protein using an antibody against the epitope tag (bottom panel). Bars show the mean and standard error for at least six
replicates.
doi:10.1371/journal.pone.0022201.g001
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mutations. The PIPS approach was clearly the most successful. It
classified the nine actual ectodomain mutations as being more
preferable than most of the distribution of all possible mutations,
and was further able to parse R222Q, V234M, and D344N as the
most favorable of these nine mutations. We took this result as
evidence that PIPS is the most promising approach for predicting
mutations that enhance neuraminidase surface-expressed protein
or activity.
Prediction of mutations that counteract the
neuraminidase defect associated with H274Y in
pandemic H1N1
We next used the PIPS computational approach to predict the
top 12 candidates for enhancing neuraminidase surface expression
from the entire set of possible mutations to the ectodomain of the
pandemic H1N1 A/California/4/2009 neuraminidase. These
predictions are shown in Table 1. Plasmids were constructed
encoding epitope-tagged H274Y neuraminidases with each of
these secondary mutations. Among the secondary mutations
discussed above as enhancing the surface-expressed activity of
seasonal H1N1 neuraminidase, D344N is already present in the
pandemic H1N1 neuraminidase. The identities of residues 222
Figure 2. PIPS is the most effective computational approach for retrospectively identifying the secondary mutations that increased
seasonal H1N1 neuraminidase surface expression and activity. The histograms show the distribution of predicted effects for all possible
single amino-acid mutations to the A/New Caledonia/20/1999 neuraminidase, for each of the four computational approaches (CUPSAT, FOLDX, the
consensus approach, and PIPS). The A/Brisbane/59/2007 strain contains nine mutations in the crystallized ectodomain portion of the neuraminidase
relative to the A/New Caledonia/20/1999 strain. The three mutations that were experimentally show to enhance neuraminidase surface expression or
activity (R222Q, V234M, and D344N) are indicated with red squares, while the other six mutations are indicated with green circles. The units for the
different prediction methods are arbitrary, but in all cases more negative numbers correspond to mutations that are predicted to be more favorable.
Shown are one-sided P-values for the hypothesis that the prediction method assigns more negative values to the known enhancing mutations (red
squares) than the other six mutations (green circles), as determined using the Mann-Whitney test. The most successful computational approach
appears to be PIPS, which correctly places all three red squares to the left of all six green circles.
doi:10.1371/journal.pone.0022201.g002
Table 1. Top twelve PIPS predicted neuraminidase mutations
to pandemic H1N1.
mutation PIPS prediction
N369K 210.08
T289M 27.79
V166A 27.04
S366K 26.74
P126N 26.51
N386E 26.45
V83M 26.15
I389S 26.01
G454N 24.97
V106I 24.95
R257K 24.89
N221K 24.87
Top predicted mutations to A/California/4/2009 neuraminidase, excluding
mutations not in crystallized ectodomain and only considering the top
prediction at each site. Mutations named in N1 numbering scheme.
doi:10.1371/journal.pone.0022201.t001
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respectively. We therefore also constructed plasmids with the
secondary mutations N222Q and V234M.
Each of these secondary mutations was tested for its effect on
the total amount of neuraminidase activity and protein expressed
on the surface of transfected cells (Figure 3). H274Y decreases
surface-expressed activity and protein to less than half of wildtype
levels. Several of the secondary mutations partially rescued this
defect, with the strongest effects being mediated by R257K,
T289M, N369K, and V234M (N1 numbering scheme). Other
secondary mutations had no effect, or even decreased neuramin-
idase surface expression, indicating that the computational
predictions are imperfect. Nonetheless, we considered it hearten-
ing that combining the computational predictions with a modest
amount of experimental screening allowed us to identify several
mutations of possible relevance.
The two secondary mutations with the strongest effects were
R257K and T289M. We constructed plasmids encoding both
mutations in the background of either wildtype or H274Y, and
measured the total surface-expressed neuraminidase activity and
protein (Figure 4). Combining both R257K and T289M with
H274Y rescued total surface-expressed activity to approximately
wildtype levels. In the absence of H274Y, these two mutations
increased total surface-expressed activity to levels 50% higher than
wildtype. Interestingly, in both backgrounds, the effects of the
R257K and T289M on the levels of surface-expressed protein
were substantially larger than those on activity. The protein levels
for the H274Y-R25K-T289M triple mutant were twice those of
wildtype, while the levels for the double mutant without H274Y
were five times higher than wildtype. This finding suggests that
these secondary mutations either decrease the per-protein
enzymatic activity, or cause a portion of the protein to reach the
cell surface in an inactive form. However, this effect is outweighed
by the overall increase in surface protein levels, such that the
secondary mutations still enhance total surface-expressed activity.
Secondary mutations eliminate the mild tissue-culture
growth defect caused by H274Y in pandemic H1N1
To test the effects of the top candidate permissive mutations on
viral growth, we used reverse genetics to generate pandemic H1N1
viruses carrying GFP in the PB1 segment [8]. These viruses
derived their gene segments from the A/California/4/2009 strain,
Figure 3. Several of the predicted secondary mutations partially counteract the decrease that H274Y causes in total surface-
expressed activity and protein for the pandemic H1N1 neuraminidase. Shown are wildtype (WT) and indicated mutants of the A/California/
4/2009 neuraminidase. All neuraminidases contain C-terminal epitope tags, except for the untagged WT. For the measurements, 293T cells were
transfected with plasmids encoding the neuraminidase proteins. After 20 hours, the cells were assayed for the total surface-expressed neuraminidase
activity (top panel) or protein using an antibody against the epitope tag (bottom panel). Bars show the mean and standard error for at least six
replicates.
doi:10.1371/journal.pone.0022201.g003
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T197A mutation (which makes the sequence match that from
the vaccine strain A/California/7/2009). We successfully rescued
viruses with wildtype, H274Y, R257K-T289M, and H274Y-
R257K-T289M neuraminidases.
We performed viral growth assays in MDCK-SIAT1 cells that
constitutively expressed the PB1 protein. As has been observed in
the majority of previous studies [24,27–30] with 2009 pandemic
H1N1 strains, we found that H274Y caused a slight decrease in
viral growth (Figure 5). Our results most closely resemble those
obtained by [29] with the A/California/4/2009 strain, with the
H274Y variant growing to slightly lower titers at all timepoints,
with a maximal difference of about 10-fold.
However, the H274Y-R257K-T289M and R257K-T289M
variants grew to titers similar to wildtype (Figure 5), suggesting
that these two secondary mutations may rescue a slight attenuation
in tissue-culture growth associated with H274Y. In the presence of
50 nM oseltamivir, neither the wildtype nor the R257K-T289M
variants grew appreciably. But both the H274Y and H274Y-
R257K-T289M variants grew as well as they had in the absence of
oseltamivir. Therefore, the secondary mutations do not greatly
affect viral resistance to oseltamivir per se, but may alleviate the
slight tissue-culture growth defect caused by H274Y.
Discussion
We have investigated the possibility of predicting secondary
mutations that counteract the decreased neuraminidase surface
expression associated with the H274Y oseltamivir resistance
mutation in pandemic H1N1. We began with a retrospective test
to find the most effective computational approach for identifying
mutations that enhanced total surface-expressed activity and
protein among all of neuraminidase mutations that occurred
during the divergence of 1999 and 2007 strains of seasonal H1N1.
We then used this computational approach to predict 12 new
candidate mutations to pandemic H1N1. Three of these
candidates (R257K, T289M, and N369K), as well as one of the
secondary mutations from seasonal H1N1 (V234M), partially
rescued the defect in surface-expressed neuraminidase activity and
protein associated with H274Y in a 2009 pandemic H1N1 strain.
Combining the two best candidates (R257K and T289M) with
H274Y restored total surface-expressed activity to wildtype levels.
These two mutations also appeared to rescue the slight defect in
tissue-culture growth associated with H274Y in pandemic H1N1.
As discussed in the Introduction, the question of whether
H274Y meaningfully attenuates pandemic H1N1 is a subject of
continuing debate [24–31]. It therefore remains unclear whether
the fact that H274Y pandemic H1N1 isolates have thus far been
evolutionary dead ends [22,23] is simply a matter of luck, or is
because they are less fit than their oseltamivir-sensitive counter-
parts. Our results cannot resolve this question, which will
ultimately be answered only by continuing to observe the natural
evolution of the virus. However, our results do clearly demonstrate
that a measurable phenotype associated with H274Y in pandemic
H1N1 – a decrease in the total amount of surface-expressed
neuraminidase protein and activity – has the potential to be
counteracted by secondary mutations. Furthermore, we have
identified four specific mutations (R257K, T289M, N369K, and
V234M) with the potential to exert this effect. Note that this is
unlikely to represent an exhaustive list of all mutations that
enhance neuraminidase surface expression, since we only
experimentally screened 14 of the nearly 9,000 possibilities.
Nonetheless, these four mutations may be worthy of monitoring
during surveillance of pandemic H1N1.
Regardless of the eventual fate of H274Y in pandemic H1N1,
our findings are relevant to broader issues in protein evolution. We
began this paper by describing the burgeoning set of examples
where a mutation causes a beneficial phenotypic alteration only
when it is paired with a secondary mutation. We further noted that
these secondary mutations often act in a general manner by
bolstering a protein-level property such as folding, stability, or
expression, thereby alleviating defects caused by a variety of other
mutations [1,5,43–48]. The potential for this phenomenon
appears to be pervasive in influenza neuraminidase, as evidenced
by the existence of multiple secondary mutations that partially
counteract the decreased surface expression caused by H274Y.
The exact biophysical mechanism remains unclear, and is an
important area for further research. However, it is interesting to
note that the mutations are scattered about the neuraminidase
protein structure (Figure 6), and so appear to be generally
promoting surface expression rather than forming a specific
structural interaction with H274Y.
Figure 4. Combining several secondary mutations can fully
counteract the effect of H274Y on surface-expressed pandemic
H1N1 neuraminidase activity. Shown are wildtype (WT) and
indicated mutants of the A/California/4/2009 neuraminidase, all
containing C-terminal epitope tags. For the measurements, 293T cells
were transfected with plasmids encoding the neuraminidase proteins.
After 20 hours, the cells were assayed for the total surface-expressed
neuraminidase activity (top panel) or protein using an antibody against
the epitope tag (bottom panel). Bars show the mean and standard error
for at least six replicates.
doi:10.1371/journal.pone.0022201.g004
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provides a basis for the strategy we used to identify potentially
important secondary mutations. The PIPS computational ap-
proach is built on the idea that a single additive dimension
captures the buffering effects of mutations on the whole set of
evolutionarily constrained protein properties. Clearly this is a
severe approximation, since mutations can have complex effects
on each of these properties. But the approximation captures
enough of the truth to be useful, since combining the resulting
computational predictions with a modest amount of experimental
screening was sufficient to identify secondary mutations that
indeed enhanced neuraminidase surface expression. Whether any
of these secondary mutations are actually found to play a role in
increasing the permissiveness of pandemic H1N1 to oseltamivir
resistance during future natural evolution will of course be the
truest test of the practical value of this approach.
Materials and Methods
PIPS computational approach for predicting secondary
mutations
The PIPS approach that we used to predict secondary
neuraminidase mutations that might enhance neuraminidase
surface expression is an improved version of that described in
[34]. The approach is based on the idea that mutations frequently
cause changes in protein-level properties that are under evolu-
tionary constraint, such as stability, folding or expression.
Previously [5,34,47,49], we cast the evolutionarily relevant
property solely as protein thermodynamic stability, DGf. Howev-
er, in the course of work by ourselves [8] and others [50,51], it has
become increasingly obvious that thermodynamic stability is not
always the protein-level property under the strongest evolutionary
constraint. We will therefore formalize a certain level of
biophysical evasiveness by defining a variable F, representing an
approximate agglomeration of evolutionarily constrained proper-
ties such as thermodynamic stability, kinetic stability, folding
efficiency, resistance to aggregation, intracellular trafficking, etc.
In this formulation, F represents the best one-dimensional
projection of all of these properties, to which in practice
mutational effects are frequently [50,52–56] but not always
[45,57] correlated. Describing each property individually would
be more biophysically accurate, but would not be mathematically
tractable in the approach that follows. The ultimate justification
for a formalism based on the biophysically approximate variable F
is experimental validation of some of the resulting predictions
described here and in [34].
More negative values of F correspond to better protein
properties, while more positive values correspond to worse
properties. We assume that evolution selects to maintain F below
some threshold (chosen here as zero) to ensure that the protein
adopts and maintains its folded conformation. However, as long as
Fv0, selection is indifferent to its exact value. When F§0,a
protein is nonfunctional. Therefore, a mutation that worsens
protein properties (increases F) will not be tolerated by a protein
that has a marginal value of F (top panel of Figure 7A). But the
same mutation is tolerated by a protein with a larger margin in F
(bottom panel of Figure 7A). This relationship between F and
mutational tolerance corresponds to the experimental observation
that more stable proteins tend to be more robust to mutations
Figure 5. Growth in tissue-culture of pandemic H1N1 variants carrying neuraminidase mutations. The plot at left shows growth in
media lacking oseltamivir, while the plot at right shows growth in media containing 50 nM oseltamivir. Viruses contain all genes from the A/
California/4/2009 strain with the T197A mutation to hemagglutinin, with the exception of the PB1 segment which is engineered to carry GFP. MDCK-
SIAT1-CMV-PB1 cells were infected with the viruses at initial multiplicities of infection of 5|10{4 infectious particles per cell. At the indicated times,
viral supernatants were harvested and titered on fresh cells. Shown are the mean and standard error for four replicates.
doi:10.1371/journal.pone.0022201.g005
Figure 6. Sites of the mutations mapped onto the neuramin-
idases protein structure. Shown in dark green is one monomer from
an N1 neuraminidase crystal structure ([37], PDB code 3BEQ]. Residue
274 (N2 numbering) is shown in red, and the sites of the secondary
mutations (N1 numbering) are shown in blue. Oseltamivir (yellow
spheres) is modeled in its binding site based on a related crystal
structure ([83], PDB code 2HU0). The other three monomers of the full
neuraminidase tetramer are shown in light green, based on modeling
from a related crystal structure ([83], PDB code 2HU0). The image was
rendered with PyMOL.
doi:10.1371/journal.pone.0022201.g006
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‘‘globally suppress’’ the deleterious effects of many other mutations
by increasing stability or folding efficiency [43–46].
Each mutation is associated with a DF value, which is the
difference between the F of the mutated protein and the wildtype
one. Most mutations worsen protein properties, corresponding to
an increase in F, or a positive DF value. Figure 7B shows a
representative distribution of DF values for all mutations to a
protein. The time-averaged probability distribution of F for an
evolving protein is determined by the balance between the
selection pressure to maintain Fv0 and the opposing pressure of
mutations with mostly positive DF values. The exact distribution
of F also depends on factors such as mutation rate, population
size, and the specific DF values associated with that protein
[49,58,59]. However, the distribution will have the general feature
that most of the time F is just marginally below the selection
threshold of zero. Figure 7C shows a representative time-averaged
probability distribution of F.
The foregoing facts lead to an obvious relationship between a
mutation’s DF value and the probability that it will be fixed during
neutral evolution. Specifically, let DFr
xy be the change in F
associated with mutating residue r from y to x. Given the above
assumptions,whenDFr
xyƒ0,themutation willalwaysbeselectively
neutral, since it will never push F over the threshold of zero. On the
other hand, when DFr
xyw0, the mutation will only be selectively
neutral if the protein possess a sufficient buffer in F, which will be
the case when FvDFr
xy. Given the time-averaged distribution of
F shown in Figure 7C, it is clear that mutations just slightly
increasing F will frequently be neutral, while mutations with very
large DFr
xy will onlyrarelybe neutral.Letf r
xy betheprobability that
the mutation is selectively neutral. The relationship between f r
xy and
DFr
xy will have the general qualitative form shown in Figure 7D.
We will use this relationship to infer DFr
xy values from the
mutational histories contained in protein phylogenies.
For each residue r, we want to infer the set fDFr
xWTg
r ðÞof the
DFr
xWT values for mutating the residue from its wildtype (WT)
identity to some other residue x. We will assume that the DFr
xWT
values for all residues are independent and additive, an assumption
that although obviously imperfect is nonetheless likely to
frequently be reasonable [60–65]. The specification of
fDFr
xWTg
r ðÞallows for calculation of arbitrary DFr
xy as
DFr
xy~DFr
xWT{DFr
yWT: ð1Þ
Figure 7. Rationale for assuming that the fixation probability of a mutation depends on its effect on evolutionarily constrained
protein properties. (A) Evolution is assumed to select in a threshold manner for properties such as folding, stability, or expression (approximated
by the variable F). A mutation deleterious to F will not be tolerated by a protein that has a marginal value of F (top panel). But the same mutation is
tolerated by a protein with an extra buffer in F (bottom panel). (B) Most mutations are deleterious to F, and therefore have positive DF values.
Shown is an example distribution of DF for all mutations to a protein, taken from [49]. (C) The time-averaged probability distribution of F for an
evolving protein will tend towards values just marginally below the threshold. Shown is an example of this distribution, taken from [49]. (D) As a
consequence, mutations with negative DF values will generally be tolerated, but those with positive DF are less likely to be tolerated. Shown is a
plot of the relationship between the probability f r
xy that mutating residue r from y to x will be tolerated as a function of the associated DFr
xy value, as
defined in Equation 3.
doi:10.1371/journal.pone.0022201.g007
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LDFr
xy
LDFr
zWT
~
1, if x~z=y
{1, if y~z=x
0, otherwise:
8
> <
> :
ð2Þ
We have described f r
xy as the probability that the mutation of
residue r from y to x goes to fixation at the neutral expectation.
Here we give an exact functional relationship between f r
xy and
DFr
xy. We have chosen this functional form arbitrarily, for simple
reasons of mathematical convenience. However, it captures the
key qualitative attributes discussed above. Specifically, we assume
that
f r
xy~
1
2
{
1
2
tanh b|DFr
xy{
1
2
ln
c
1{c
     
, ð3Þ
where bw0 is a constant describing the steepness of the curve and
c gives the value of f r
xy at DFr
xy~0. We use a range of g~20 and
constrain {gvDFr
xWTvg. We set c~0:8, and then choose
b~0:265 so that 10{4~
1
2
{
1
2
tanh b|g{
1
2
ln
c
1{c
     
.
Equation 3 is plotted in Figure 7D. The corresponding derivatives
are
Lf r
xy
LDFr
xy
~2bf r
xy f r
xy{1
  
, ð4Þ
and so by the chain rule,
Lf r
xy
LDFr
zWT
~
2bf r
xy f r
xy{1
  
if x~z=y
{2bf r
xy f r
xy{1
  
if y~z=x
0 otherwise:
8
> > > <
> > > :
ð5Þ
As in [34], define Gr as the matrix with elements
Gr
xy~
f r
xy cxy,i f x=y
{
P
z=y
f r
zy czy,i f x~y
8
<
:
, ð6Þ
where cxy is the probability that a random nucleotide mutation to
a codon for amino acid y changes this codon to be for amino acid
x. We refer to the set of all cxy values as C. Again using the chain
rule,
LGr
xy
DFr
zWT
~
cxy|2bf r
xy f r
xy{1
  
if z~x=y
{cxy|2bf r
xy f r
xy{1
  
if z~y=x
{czy|2bf r
zy f r
zy{1
  
if x~y=z
X
w=y
cwy|2bf r
wy f r
wy{1
  
if x~y~z
0 otherwise:
8
> > > > > > > > > > > <
> > > > > > > > > > > :
ð7Þ
The probability that a substitution changes residue r from y to x
after an elapsed time t is given by element Mr
xy t ðÞof the matrix
Mr t ðÞdefined by
Mr t ðÞ ~exp utGr ðÞ , ð8Þ
where u is the per codon mutation rate. Let Dr be the diagonal
matrix with entries equal to the eigenvalues of Gr, let Sr be the
matrix with columns equal to the right eigenvectors of Gr, and let
S
{1
r be the inverse of Sr, so that
Gr~SrDrS
{1
r : ð9Þ
The matrix Mr t ðÞis conveniently computed as
Mr t ðÞ ~Srexp utDr ðÞ S
{1
r : ð10Þ
The derivatives of Mr t ðÞare given by [66] as
LMr t ðÞ
LDFr
zWT
~SrVr,zS
{1
r , ð11Þ
where the elements of Vr,z are
Vr,z
xy~
Br,z
xy
exp utDr
xx ðÞ {exp utDr
yy
  
Dr
xx{Dr
yy if x=y
Br,z
xx utexp Dr
xx ut
  
if x~y,
8
<
:
ð12Þ
where Dr
xx and Dr
yy are the diagonal elements of Dr representing
the eigenvalues of Gr, and Br,z
xy are the elements of the matrix Br,z
defined by
Br,z~S
{1
r
LGr
LDFr
zWT
Sr: ð13Þ
Let the probability pr
x of finding residue x at position r in the
long-time limit be given by element x of the vector pr. The vector
pr represents the stationary solution to Equation 8, and so is the
probability vector (entries sum to one) that satisfies the eigenvector
equation
pr~ IzGr ðÞ pr, ð14Þ
where I is the identity matrix. Given a value of Gr, the uniqueness
of pr is guaranteed by the Perron-Frobenius theorems, since IzGr
is a nonnegative and acyclic stochastic matrix. The derivatives of
pr are given by [67] as
Lpr
LDFr
zWT
~{ Gr ðÞ
# LGr
LDFr
zWT
pr, ð15Þ
where Gr ðÞ
# is the group inverse of Gr as described in [68].
In practice, we want to infer fDFr
xWTg from a phylogeny built
from a set of protein sequences. Let S~ skj1ƒkƒN
  
consists of
N aligned homologous sequences of length L, with sk denoting the
kth sequence. For each sequence sk, we know the identity sk
r of the
amino acid at position r (where 1ƒrƒL). The set of amino acid
identities for all N proteins at a single site r is denoted by
S
r ðÞ ~ sk
rj1ƒkƒN
  
. Let T be the phylogenetic tree giving the
relationship among these sequences. The probability of S given
fDFr
xWTg, the set C of cxy values, the mutation rate u, and the tree
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Pr SjfDFr
xWTg,C,u,T
  
~ P
L
r~1
Pr S
r ðÞ jfDFr
xWTg
r ðÞ ,C,u,T
  
: ð16Þ
For the example tree in Figure 8,
Pr S
r ðÞ jfDFr
xWTg
r ðÞ ,C,u,T
  
~
X
x,y,z,w
Pr A,C,D,E,F,x,y,z,wjfDFr
xWTg,C,u,T
  
:
ð17Þ
Using the pruning approach of [69,70],
Pr S
r ðÞ jfDFr
xWTg
r ðÞ ,C,u,T
  
~
X
x
pr
x
X
y
Mr
yx t6 ðÞ |Mr
Ay t1 ðÞ |Mr
Cy t2 ðÞ
 !
|
X
z
Mr
zx t8 ðÞ |Mr
Dz t3 ðÞ |
X
w
Mr
wz t7 ðÞ |Mr
Ew t4 ðÞ |Mr
Fw t5 ðÞ
"#  !
:
ð18Þ
The derivatives of Equation 18 can be computed using the
recursive nature of the likelihood calculation. This is most easily
seen by introducing the notation where Lr
n q ðÞrepresents the
likelihood that node n has residue q at position r given all the data
in the subtree rooted at node n. With this notation, Equation 18 is
Pr S
r ðÞ jfDFr
xWTg
r ðÞ ,C,u,T
  
~
X
x
pr
xLr
9 x ðÞ , ð19Þ
where the likelihoods are calculated recursively down to the tree
tips, so that for example,
Lr
9 x ðÞ ~
X
y
Mr
yx t6 ðÞ Lr
6 y ðÞ
 !
X
z
Mr
zx t8 ðÞ Lr
8 z ðÞ
 !
, ð20Þ
and
Lr
8 z ðÞ ~Mr
Dz t3 ðÞ |
X
w
Mr
wz t7 ðÞ Lr
7 w ðÞ
 !
: ð21Þ
Using this representation,
LPr S
r ðÞ jfDFr
xWTg
r ðÞ ,C,u,T
  
LDFr
qWT
~
X
x
Lpr
x
DFr
qWT
Lr
9 x ðÞ zpr
x
LLr
9 x ðÞ
LDFr
qWT
 ! ð22Þ
where the derivatives of the pr
x values are given by Equation 15,
and the derivatives of the likelihoods are calculated recursively, as
for example,
LLr
9 x ðÞ
LDFr
qWT
~
X
y
LMr
yx
LDFr
qWT
Lr
6 y ðÞ zMr
yx
LLr
6 y ðÞ
LDFr
qWT
 ! "#
X
z
Mr
zx t8 ðÞ Lr
8 z ðÞ
 !
z
X
y
Mr
yx t6 ðÞ Lr
6 y ðÞ
 !
X
z
LMr
zx
LDFr
qWT
Lr
8 z ðÞ zMr
zx
LLr
8 z ðÞ
LDFr
qWT
 ! "#
,
and
LLr
8 z ðÞ
LDFr
qWT
~
LMr
Dz t3 ðÞ
LDFr
qWT
X
w
Mr
wz ty
  
Lr
7 w ðÞ
 !
z
Mr
Dz t3 ðÞ |
X
w
LMr
wz t7 ðÞ
LDFr
qWT
Lr
7 w ðÞ zMr
wz t7 ðÞ
LLr
7 w ðÞ
LDFr
qWT
 ! "#
,
ð24Þ
where the derivatives of the Mr
yx are given by Equation 11.
As discussed in [34], a prior probability distribution can be
specified for each DFr
xWT value. These priors can introduce
specific biophysical knowledge as might be computed using
molecular modeling programs, or can simply serve a ‘‘regular-
izing’’ role [71] to avoid overfitting the DFr
xWT values. The
priors also enforce the constraint that {gvDFr
xWTvg.W e
define the prior probability distributions as beta distributions
peaked at a prior estimate DFr
xWT,PRIOR for the DFr
xWT in
question, and with the sum of the beta distribution a and b
parameters equal to Bsum,
Pr DFr
xWT
  
~
DFr
xWTzg
   a{1 g{DFr
xWT
   b{1
B a,b ðÞ 2g ðÞ
azb{1 ð25Þ
Figure 8. An example phylogenetic tree T . This tree shows the
sequence data S
r ðÞfor five sequences at a single site r. The amino acid
codes at the tips of the branches (A, C, D, E, and F) show the residue
identities for the five sequences at this site. The variables at the internal
nodes (x, y, z, w) are the amino acid identities at the site for the
ancestral sequences, and must be inferred. The numbers next to the
nodes are unique identifiers for the nodes. The branch lengths (t1, t2,…)
are proportional to the time since the divergence of the sequences.
doi:10.1371/journal.pone.0022201.g008
(23)
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DFr
xWT, PRIORzg
  
Bsum{2 ðÞ
2g
z1,a n db~Bsum{a.N o t et h a tDFr
xWT,PRIOR must satisfy
{gvD Fr
xWT, PRIORvg. The derivative of Equation 25 is
LPr DFr
xWT
  
LDFr
xWT
~Pr DFr
xWT
   a{1
DFr
xWTzg
{
b{1
g{DFr
xWT
  
: ð26Þ
The overall prior probability of the set of fDFr
xWTg
r ðÞof DFr
xWT
values for residue r is simply the product of the prior
probabilities for the individual DFr
xWT values,
Pr fDFr
xWTg
r ðÞ
  
~ P
DFr
xWT
Pr DFr
xWT
  
, ð27Þ
so the derivative is
LPr fDFr
xWTg
r ðÞ
  
LDFr
xWT
~Pr fDFr
xWTg
r ðÞ
   a{1
DFr
xWTzg
{
b{1
g{DFr
xWT
  
:
ð28Þ
Equations 16 and 18 provide a method for computing
Pr SjfDFr
xWTg,C,u,T
  
. But goal is to infer the fDFr
xWTg, which
is equivalent to computing Pr fDFr
xWTgjS
  
. Using Bayes’
Theorem,
Pr fDFr
xWTgjS
  
~
X
C,u,T
Pr fDFr
xWTg,C,u,T
  
Pr SjfDFr
xWTg,C,u,T
  
P
fDFr
xWTgPr fDFr
xWTg,C,u,T
  
Pr SjfDFr
xWTg,C,u,T
   :
ð29Þ
Rather than solving for all of the unknown variables, here we will
take the computational shortcut of using other methods to assign
fixed values to C, u, and T , so that
Pr fDFr
xWTgjS
  
~
Pr fDFr
xWTg
  
Pr SjfDFr
xWTg,C,u,T
  
P
fDFr
xWTg Pr fDFr
xWTg
  
Pr SjfDFr
xWTg,C,u,T
   :
ð30Þ
Furthermore, rather than fully solving the right-hand side of
Equation 30 as might in principle be done using Markov-chain
Monte Carlo methods [72–74], we will simply compute the
maximum a posteriori value fD ^ F Fr
xWTg of fDFr
xWTg, defined as
fD ^ F Fr
xWTg~
argmax
fDFr
xWTg
Pr fDFr
xWTg
  
Pr SjfDFr
xWTg,C,u,T
     
:ð31Þ
Above we have provided equations for all of the derivatives
necessary to perform this maximization using gradient-based
techniques.
Implementation of the computational approach in the
PIPS program
A computer program that solves Equation 27 to infer fDFr
xWTg
was written in the Python programming language and given the
name PIPS (Phylogenetic Inference of Protein Stability), version
1.0. This program and the raw data from the analyses described in
this paper will be made freely available at http://labs.fhcrc.org/
bloom/.
As input to the PIPS program, we used MUSCLE [75] to build
a multiple-sequence alignment of all 3,731 unique full-length N1
neuraminidase protein sequences that were available for download
from either NCBI’s Influenza Virus Resource ([76], http://www.
ncbi.nlm.nih.gov/genomes/FLU/FLU.html) or GISAID’s EpiFlu
Database ([77], http://platform.gisaid.org/) as of June 21, 2010.
The aligned sequences were then used to build a neighbor-joining
phylogenetic tree without a molecular clock, using the PHYLIP
package [78]. This tree was used as input to the PIPS program.
The PIPS program was used to compute the fDFr
xWTg values
for mutations to the neuraminidases from the seasonal H1N1
strain A/New Caledonia/20/1999 and the pandemic H1N1 strain
A/California/4/2009. The prior probability distributions in
Equation 22 were set so that all mutations had prior estimates of
D Fr
xWT, PRIOR~5, based on the idea that most mutations will be
moderately deleterious to F. The value of Bsum in Equation 22
was set to three. The mutation biases given by C in Equation 6
were calculated by assuming that each amino acid is equally likely
to be encoded by any of its possible codons, and that nucleotide
mutations occur with a transition-to-transversion ratio of four. The
value of u in Equation 8 was set to 10. The maximization in
Equation 31 was performed using the conjugate-gradient algo-
rithm. Although this algorithm is deterministic given specific
starting values, there may be local maxima. Therefore, for each
residue we performed five different maximizations starting from
different randomly chosen DFr
xWT values, and used the values that
gave the highest a posteriori probability as the final estimates.
Running the program in this fashion gave the PIPS predictions
shown in Figure 2 for the specified mutations to the neuraminidase
from A/New Caledonia/20/1999. For the mutations to the
neuraminidase from A/California/4/2009, Table 1 lists the 12
mutations with the most negative predicted DFr
xWT values,
considering only the best mutation for each residue and only
residues found in the ectodomain of the crystal structure of a
closely related N1 neuraminidase ([37], PDB code 3BEQ).
CUPSAT, FoldX, and consensus predictions
We also used CUPSAT, FoldX, and the consensus approach to
predict the effects of mutations to the A/New Caledonia/20/1999
(H1N1) neuraminidase, as shown in Figure 2. Text files giving all
of these predictions are available along with the PIPS program and
raw data that are being made available at http://labs.fhcrc.org/
bloom/.
CUPSAT and FoldX both take as their input a protein’s
structure. We used the crystal structure from PDB code 3BEQ
[37], which is of the 1918 H1N1 influenza neuraminidase. This
neuraminidase aligns to that of A/New Caledonia/20/1999 with
no gaps and 89% protein identity over the 385 residues in the
crystallized ectodomain. For the CUPSAT predictions, this
protein structure was submitted to the webserver http://cupsat.
tu-bs.de/cupsat/custompdb.htm to generate predictions for all
single mutations. For FoldX, we made the predictions using the
FoldX executable version 3.0 beta 4 for Mac OS X, as
downloaded from http://foldx.crg.es/. The FoldX ‘‘RepairPDB’’
function was first run to refine the PDB structure. The predictions
were then made using the default parameters and the ‘‘Position-
Scan’’ function. For the 89% of the residues in which the A/New
Caledonia/20/1999 neuraminidase sequence exactly matched
that in the 3BEQ crystal structure, the predicted mutational effects
were simply the predictions for that mutation. For residues that
differed between the two sequences, the predicted mutational
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residue to the target amino acid minus the predicted effect of
mutating the PDB residue to the A/New Caledonia/20/1999
residue. For both CUPSAT and FoldX, highly destabilizing
mutations (values greater than the leftmost histogram bar shown in
Figure 2) are counted in this last bar to avoid having to
dramatically expand the x-axis of the plot in the positive direction.
For the consensus predictions, we used the same sequence data
set of 3,731 full-length N1 neuraminidases that is described above
for the PIPS program. The predicted effect of mutating a residue
from amino acid x to y was calculated as ln
Nyz1
Nxz1
where Nx and
Ny are the number of sequences that have amino acids x and y at
that position, respectively. The one in the formula represents a
single pseudocount added to each sequence tally to avoid
undefined values for mutations to residues that are not present
in the natural sequence alignment.
Neuraminidase surface expression and activity assays
To test the effect of the predicted permissive mutations on the
levels of surface-expressed neuraminidase activity and protein, we
created plasmids encoding various mutants with C-terminal HA
epitope tags. Each neuraminidase protein-coding sequence was
directly fused to the epitope tag (YPYDVPDYA) and inserted into
a plasmid (HDM) containing a CMV promoter and 59 EcoRI/39
NotI cloning sites, followed by an internal ribosome entry site
(IRES) expressing the mCherry red fluorescent protein. As was
previously observed [8], the addition of the C-terminal epitope tag
led to at most a slight (less than 10%) decrease in the total surface-
expressed neuraminidase activity relative to an untagged variant
(Figures 1 and 3), indicating that the tag did not substantially alter
the protein or activity levels. Plamids were constructed for all of
the mutants of the A/New Caledonia/20/1999 neuraminidase
shown in Figure 1 and all of the mutants of the A/California/4/
2009 neuraminidase shown in Figures 3 and 4. In the naming of
the mutations, H274Y was named in the N2 numbering scheme to
adhere to historical convention – this is actually residue 275 in
sequential numbering of the N1 neuraminidase. All of the other
mutations are named according sequential N1 neuraminidase
numbering.
For the assays, the plasmids were transfected into 293T cells in
12-well dishes that had been seeded at uniform densities of 2|105
cells per well. At 20 hours post-transfection, the cells were
collected using a very brief treatment with EDTA-trypsin, and
resuspended in an isotonic assay buffer at pH 7.4, consisting of
15 mM MOPS, 145 mM sodium chloride, 2.7 mM potassium
chloride, 4.0 mM calcium chloride, and 2% heat-inactivated fetal
bovine serum. A fraction of these cells (5% of the total number
collected per well) were then assayed for the total neuraminidase
activity expressed on the cell surface using the fluorogenic
MUNANA assay. For this assay, the cells were incubated with
0.1 mM MUNANA (Sigma M8639) in a total volume of 150 mli n
black 96-well plates at 370C for 45 minutes. The reactions were
quenched by adding 100 ml of 150 mM sodium hydroxide in 84%
ethanol. The fluorescence was read using a Tecan Safire 2 plate
reader (excitation 360 nm, slit width 5 nm; emission 448 nm, slit
width 20 nm). The activities were quantified as the fluorescence
above the background from untransfected cells, normalized by the
fraction of cells transfected with the plasmid as determined by flow
cytometry for mCherry fluorescence as described below. Each bar
for the activity measurements in Figures 1, 3, 4 represents the
mean and standard error for at least six individual measurements.
A remaining fraction of the cells were stained with a
fluorescently conjugated antibody against the epitope tag (Santa
Cruz Biotechnology, HA probe F-7 Alexa-Fluor 647 conjugate, sc-
7392 AF647, 1:100 dilution). The stained cells were analyzed by
flow cytometry to determine the fraction of cells expressing the
mCherry protein (these are the cells transfected with the plasmid),
and the mean signal from the antibody staining among these
mCherry positive cells. The staining signal above background was
assumed to be proportional to the amount of neuraminidase
protein on the cell surface. Each bar for the stain measurements in
Figures 1, 3, 4 represents the mean and standard error of at least
six individual measurements.
Viral growth assays
Reverse genetics plasmids for the A/California/4/2009 H1N1
strain were constructed by using reverse-transcriptase PCR to
amplify the genome segments from total RNA extracted from virus
obtained from the Biodefense and Emerging Infections Resource
Repository (BEI Resources, catalog number NR-13658). The
hemagglutinin gene for A/California/4/2009 was modified by
adding the T197A mutation, since this mutation is present in the
majority of 2009 pandemic H1N1 isolates including the A/
California/7/2009 vaccine strain, and has been reported to aid in
virus rescue by reverse genetics [79]. The gene segments were
cloned into the BsmBI sites of the bidirectional RNA polymerase
I/polymerase II cassette plasmid pHW2000 [80], which was
kindly provided by Robert Webster of St. Jude Children’s
Research Hospital. Mutations to the neuraminidase were
introduced by site-directed mutagenesis.
Virions carrying GFP in the PB1 segment were rescued as
described in [8]. Briefly, the plasmid pHH-PB1flank-eGFP
encodes a viral RNA with the untranslated regions and 80
terminal coding nucleotides from each end of the PB1 gene
segment from A/WSN/33 influenza, with potential start codons
mutated. This plasmid and the reverse genetics plasmids for the
other seven influenza segments (PB2, PA, HA, NP, NA, M, and
NS) were co-transfected into a co-culture of 293T (ATCC
CRL11268) and MDCK-SIAT1 ([81], HPA Cultures 05071502)
cells that constitutively expressed the A/WSN/33 PB1 protein
under a CMV promoter (293T-CMV-PB1 and MDCK-SIAT1-
CMV-PB1 cells), with the PB1-F2 peptide eliminated by
introduction of a stop codon in the manner described by [82].
At 12 hours post-transfection, the cells were washed once with
PBS and the media changed to influenza growth media (Opti-
MEM I supplemented with 0.3% bovine serum albumin, 0.01%
heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100
mg/ml streptomycin, and 100 mg/ml calcium chloride) containing
3 mg/ml TPCK-treated trypsin. After another 60 hours, at which
point essentially all cells had turned green and were undergoing
visible cytopathic effect, the viruses were harvested by filtration
through a 0.45 mm filter. The viruses were titered by infecting
MDCK-SIAT1-CMV-PB1 cells in influenza growth media, and
then quantifying the percentage of GFP positive cells at 15 hours
post-infection using flow cytometry. Each virus variant (wildtype,
H274Y, R257K-T289M, and H274Y-R257K-T289M neuramin-
idase) was rescued and titered in duplicate.
For the growth assays, MDCK-SIAT1-CMV-PB1 cells were
seeded in 6-well dishes so that they were at 6|105 cells per well at
the time of viral infection. Immediately before infection, the
medium was changed to 3 ml of influenza growth media plus
3 mg/ml TPCK-trypsin. Some wells also contained 50 nM
oseltamivir carboxylate (kindly provided by J. Smith and A. Perrin
of F. Hoffmann-La Roche), as indicated in Figure 5. Each well was
then infected with an amount of virus equal to 300 infectious
particles according to the flow cytometry titering. At the time
points indicated in the figures, supernatant was collected and the
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SIAT1-CMV-PB1 cells. Each point in the figures shows the mean
and standard deviation for four total replicates, with two replicates
performed with each of the two separate virus rescues. The
exceptions are the measurements for the wildtype and R257K-
T289M viruses in 50 nM oseltamivir, where only two total
replicates were performed (one with each of the two separate virus
rescues).
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